These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 18513919

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation.
    Fong A, Garcia E, Gwynn L, Lisanti MP, Fazzari MJ, Li M.
    Am J Clin Pathol; 2003 Jul; 120(1):93-100. PubMed ID: 12866378
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of the vascular endothelial growth factor (VEGF)-C role in urothelial carcinomas of the bladder.
    Mylona E, Magkou C, Gorantonakis G, Giannopoulou I, Nomikos A, Zarogiannos A, Zervas A, Nakopoulou L.
    Anticancer Res; 2006 Jul; 26(5A):3567-71. PubMed ID: 17094484
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue.
    Feil G, Maurer S, Nagele U, Krug J, Bock C, Sievert KD, Stenzl A.
    Eur Urol; 2008 May; 53(5):1066-72. PubMed ID: 17980954
    [Abstract] [Full Text] [Related]

  • 32. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer.
    Cardillo MR, Castagna G, Memeo L, De Bernardinis E, Di Silverio F.
    J Exp Clin Cancer Res; 2000 Jun; 19(2):225-33. PubMed ID: 10965823
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
    Matsumoto K, Satoh T, Irie A, Ishii J, Kuwao S, Iwamura M, Baba S.
    Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
    [Abstract] [Full Text] [Related]

  • 35. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
    Mhawech-Fauceglia P, Alvarez V, Fischer G, Beck A, Herrmann FR.
    Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
    [Abstract] [Full Text] [Related]

  • 36. A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma.
    Adam RM, Danciu T, McLellan DL, Borer JG, Lin J, Zurakowski D, Weinstein MH, Rajjayabun PH, Mellon JK, Freeman MR.
    Cancer Res; 2003 Jan 15; 63(2):484-90. PubMed ID: 12543806
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases.
    Jones TD, Kernek KM, Yang XJ, Lopez-Beltran A, MacLennan GT, Eble JN, Lin H, Pan CX, Tretiakova M, Baldridge LA, Cheng L.
    Hum Pathol; 2005 Jul 15; 36(7):718-23. PubMed ID: 16084939
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.